Elevated D-dimer as an immediate response to alemtuzumab treatment

Area of Science:

• Neuroimmunology
• Hematology
• Pharmacology

Background:

• Alemtuzumab effectively reduces inflammation in highly active multiple sclerosis by depleting immune cells.
• Infusion-associated reactions are common adverse events linked to cytokine release post-alemtuzumab administration.
• Recent reports highlight serious cardiovascular and thrombotic events following alemtuzumab treatment.

Purpose of the Study:

• To investigate the impact of alemtuzumab on coagulation parameters in multiple sclerosis patients.
• To assess the dynamics of coagulation activation during alemtuzumab therapy.
• To evaluate the potential thrombotic risk associated with alemtuzumab treatment.

Main Methods:

• Analysis of coagulation parameters in 13 multiple sclerosis patients undergoing alemtuzumab treatment.
• Monitoring D-dimer levels immediately following alemtuzumab administration.
• Observational study design to track changes in coagulation markers.

Main Results:

• A significant and immediate increase in D-dimer levels was observed after the first alemtuzumab dose.
• This D-dimer elevation indicates activation of the coagulation system.
• The findings suggest a potential pro-thrombotic effect of alemtuzumab therapy.

Conclusions:

• Alemtuzumab treatment is associated with acute coagulation activation in multiple sclerosis patients.
• The observed D-dimer increase signals a potential risk for thrombotic complications.
• Prophylactic administration of low molecular weight heparin may be advisable before alemtuzumab infusion.